Target intelligence / Profile preview

Alpha-melanocyte-stimulating hormone (α-MSH)

Target
α-MSH
Molecular classification
Peptide hormone, Neuropeptide, Melanocortin family
01

Overview

**Alpha-melanocyte-stimulating hormone** (**α-MSH**) is an endogenous tridecapeptide hormone derived from proopiomelanocortin cleavage. It belongs to the melanocortin family and acts primarily by binding to several subtypes of melanocortin receptors—most notably MC1R on skin/hair cells for pigmentation effects but also centrally acting on MC3R/MC4R to regulate appetite and energy balance. In addition to its role in stimulating melanin production after UV exposure—which helps protect against DNA damage—it exerts anti-inflammatory effects across various tissues by modulating cytokine expression. In clinical medicine its synthetic analogs are used for rare photodermatoses like erythropoietic protoporphyria as well as hypoactive sexual desire disorder; investigational uses include obesity treatment via central appetite pathways. While not itself a direct therapeutic target like a receptor or enzyme—rather serving as an endogenous ligand—its downstream signaling axis is targeted pharmacologically through agonist analogs with improved potency/selectivity profiles compared to native peptide. The biological roles extend beyond pigmentation into metabolism regulation, inflammation control/protection from tissue injury after ischemia-reperfusion events—and possibly influence psychiatric disease risk via neuroendocrine circuits. The term "Alpha-melanocyte-stimulating hormone" refers specifically to the peptide ligand—not its primary pharmacological targets which are the various **melanocortin receptors**.[1][2][3] **Note:** There is something incorrect about using "Alpha-melanocyte-stimulating hormone" as a *therapeutic target* per se—it is not itself considered a classic druggable target like a receptor/enzyme/transporter but rather an endogenous ligand whose pathway can be modulated therapeutically by mimetic drugs.[1]

Other names
Alpha-MSHα-MSHAlpha-melanotropinMelanotropin alpha
02

Mechanism of action

Drugs acting on this pathway are typically **agonists** at melanocortin receptors, especially MC1R, MC3R, MC4R, and sometimes MC5R. Their effects include stimulation of melanin synthesis in melanocytes, suppression of appetite via hypothalamic pathways, modulation of sexual function through central nervous system mechanisms, and anti-inflammatory/cytoprotective actions[1][2][9].

03

Biological functions

Stimulation of melanogenesis (melanin production)Regulation of energy homeostasis and appetite suppressionModulation of sexual behavior and arousalProtection against ischemia-reperfusion injury (cytoprotection)Modulation of inflammatory responses
04

Disease associations

Pigmentation disorders (e.g., vitiligo, erythropoietic protoporphyria)Obesity/metabolic syndrome (via central appetite regulation)Melanoma and other skin cancers (role in tumor biology is complex and context-dependent)Psychiatric disorders such as schizophrenia and PTSD (as part of the POMC/α-MSH system)
05

Safety considerations

Notable safety concerns with α-MSH analogs include nausea, headache, spontaneous penile erection/priapism, fatigue, skin hyperpigmentation; administration route risks exist due to injectable formulations. There is also concern about immune modulation potentially aiding tumor immune escape in melanoma contexts[7][9].
06

Interacting drugs

Afamelanotide

3 more in the full profile.

07

Biomarkers

No widely established clinical biomarkers specific to α-MSH itself; however, Proopiomelanocortin (POMC) methylation status has been proposed as a biomarker for metabolic syndrome risk in psychiatric populations[6].Expression levels or activity at melanocortin receptors may be relevant in research settings.

Beyond the preview

Go deeper on Alpha-melanocyte-stimulating hormone (α-MSH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-melanocyte-stimulating hormone (α-MSH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call